Literature DB >> 22901104

Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study.

Robin Haring1, Zhaoyang Teng, Vanessa Xanthakis, Andrea Coviello, Lisa Sullivan, Shalender Bhasin, Joanne M Murabito, Henri Wallaschofski, Ramachandran S Vasan.   

Abstract

BACKGROUND: Emerging data from longitudinal studies suggest that low sex steroid concentrations in men are associated with increased cardiovascular risk and mortality. The impact of longitudinal trajectory patterns from serial sex steroid and gonadotrophin measurements on the observed associations is unknown to date.
METHODS: We prospectively evaluated 254 elderly men (mean age, 75·5 years) of the Framingham Heart Study with up to four serial measurements of serum total testosterone (TT), dehydroepiandrosterone sulphate (DHEAS), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and total estradiol (EST); and constructed age- and multivariable-adjusted Cox proportional hazard regression models relating baseline hormone concentrations and their mean, slope and variation over time (modelled as continuous and categorized into quartiles) to the incidence of clinical cardiovascular disease (CVD) and all-cause mortality at 5- and 10-year follow-up.
RESULTS: We observed no association between baseline concentrations of sex steroids, gonadotrophins and their trajectories with incident clinical CVD over 5- and 10-year follow-up. Although higher baseline TT concentrations were associated with lower mortality risk at 5 years (hazard ratio per quartile increment, 0·74; 95% confidence interval, 0·56-0·98), correction for multiple statistical testing (P < 0·005) rendered this association statistically nonsignificant. Repeat analyses at the 10-year follow-up time point also demonstrated no significant association between sex steroids, gonadotrophins or their trajectories and mortality.
CONCLUSION: Investigating longitudinal trajectory patterns of serial sex steroid and gonadotrophin measurements, the present study found no consistent associations with incident clinical CVD and all-cause mortality risk in elderly men from the community.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22901104      PMCID: PMC4161203          DOI: 10.1111/cen.12013

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  23 in total

1.  Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men.

Authors:  Varant Kupelian; Stephanie T Page; Andre B Araujo; Thomas G Travison; William J Bremner; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2006-01-04       Impact factor: 5.958

2.  Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study.

Authors:  Kay-Tee Khaw; Mitch Dowsett; Elizabeth Folkerd; Sheila Bingham; Nicholas Wareham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Circulation       Date:  2007-11-26       Impact factor: 29.690

3.  Epidemiological approaches to heart disease: the Framingham Study.

Authors:  T R DAWBER; G F MEADORS; F E MOORE
Journal:  Am J Public Health Nations Health       Date:  1951-03

4.  High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden.

Authors:  Claes Ohlsson; Elizabeth Barrett-Connor; Shalender Bhasin; Eric Orwoll; Fernand Labrie; Magnus K Karlsson; Osten Ljunggren; Liesbeth Vandenput; Dan Mellström; Asa Tivesten
Journal:  J Am Coll Cardiol       Date:  2011-10-11       Impact factor: 24.094

5.  Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study.

Authors:  George Davey Smith; Yoav Ben-Shlomo; Andrew Beswick; John Yarnell; Stafford Lightman; Peter Elwood
Journal:  Circulation       Date:  2005-07-11       Impact factor: 29.690

6.  Endogenous sex hormones and cardiovascular disease incidence in men.

Authors:  Johan Arnlöv; Michael J Pencina; Shreyasee Amin; Byung-Ho Nam; Emelia J Benjamin; Joanne M Murabito; Thomas J Wang; Philip E Knapp; Ralph B D'Agostino; Shalendar Bhasin; Ramachandran S Vasan
Journal:  Ann Intern Med       Date:  2006-08-01       Impact factor: 25.391

7.  Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study.

Authors:  J W Yarnell; A D Beswick; P M Sweetnam; D Riad-Fahmy
Journal:  Arterioscler Thromb       Date:  1993-04

8.  Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study.

Authors:  S Amin; Y Zhang; C T Sawin; S R Evans; M T Hannan; D P Kiel; P W Wilson; D T Felson
Journal:  Ann Intern Med       Date:  2000-12-19       Impact factor: 25.391

9.  Sex steroids and all-cause and cause-specific mortality in men.

Authors:  Andre B Araujo; Varant Kupelian; Stephanie T Page; David J Handelsman; William J Bremner; John B McKinlay
Journal:  Arch Intern Med       Date:  2007-06-25

10.  Low serum testosterone and mortality in older men.

Authors:  Gail A Laughlin; Elizabeth Barrett-Connor; Jaclyn Bergstrom
Journal:  J Clin Endocrinol Metab       Date:  2007-10-02       Impact factor: 5.958

View more
  20 in total

1.  Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study.

Authors:  D D Ørsted; B G Nordestgaard; S E Bojesen
Journal:  Ann Oncol       Date:  2014-03       Impact factor: 32.976

2.  The implications of low testosterone on mortality in men.

Authors:  Molly M Shores
Journal:  Curr Sex Health Rep       Date:  2014-12-01

Review 3.  Testosterone, myocardial function, and mortality.

Authors:  Vittorio Emanuele Bianchi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

4.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 5.  Testosterone, aging and survival: biomarker or deficiency.

Authors:  Molly M Shores; Alvin M Matsumoto
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-06       Impact factor: 3.243

6.  Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome.

Authors:  P Iglesias; F Prado; M C Macías; M T Guerrero; A Muñoz; E Ridruejo; P Tajada; C García-Arévalo; J J Díez
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

Review 7.  Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction.

Authors:  Biljana Musicki; Anthony J Bella; Trinity J Bivalacqua; Kelvin P Davies; Michael E DiSanto; Nestor F Gonzalez-Cadavid; Johanna L Hannan; Noel N Kim; Carol A Podlasek; Christopher J Wingard; Arthur L Burnett
Journal:  J Sex Med       Date:  2015-12-08       Impact factor: 3.802

8.  Testosterone and cardiac mass and function in men with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC).

Authors:  Catherine Kim; Ionut Bebu; Barbara Braffett; Patricia A Cleary; Valerie Arends; Michael Steffes; Hunter Wessells; Trevor Orchard; Aruna V Sarma
Journal:  Clin Endocrinol (Oxf)       Date:  2016-01-25       Impact factor: 3.478

Review 9.  Testosterone deficiency in the aging male.

Authors:  J Abram McBride; Culley C Carson; Robert M Coward
Journal:  Ther Adv Urol       Date:  2016-02

Review 10.  Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations.

Authors:  Nikolai Jaschke; Andrew Wang; Lorenz C Hofbauer; Martina Rauner; Tilman D Rachner
Journal:  Ageing Res Rev       Date:  2021-02-18       Impact factor: 10.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.